PRINCETON, N.J., and PARIS, Nov. 23 /PRNewswire-FirstCall/ -- Bristol-
Myers Squibb Company (NYSE: BMY) and Pierre Fabre Medicament reported today
that they are terminating their license agreement for the development of
vinflunine, a chemotherapy agent under investigation for the treatment of
advanced or metastatic bladder cancer and other tumor types. Vinflunine was
developed by Pierre Fabre Medicament and licensed to Bristol-Myers Squibb
in 2004 for specific territories. Based on a review of the clinical
development program and the decision not to file a new drug application for
bladder cancer in the United States, coupled with an analysis of
Bristol-Myers Squibb's Research & Development priorities, the companies
have jointly decided that all rights licensed to Bristol-Myers Squibb for
vinflunine will be returned to Pierre Fabre Medicament.
"In Europe, Pierre Fabre Medicament intend to continue discussions with
regulatory authorities and plan to file for the registration of vinflunine
for bladder cancer in the first quarter of 2008," said P. Hurteloup,
General Manager of Pierre Fabre Medicament Oncology Division. "We also are
considering a range of further development options, including pursuing the
product on a worldwide basis for the treatment of a number of cancers."
Bristol-Myers Squibb is a global pharmaceutical and related health care
products company whose mission is to extend and enhance human life.
Pierre Fabre Medicament is a French private group dedicated to
consumers and patients from health to beauty.
SOURCE Bristol-Myers Squibb Company; Pierre Fabre Medicament
 back to top
Related links:
http://www.bms.com/
CONTACT:
Madeline Malia of Bristol-Myers Squibb
Company , +1-609-252-3347, madeline.malia@bms.com; Caroline
Perdrix of Pierre Fabre Medicament, 00 331 49 10 81 12,
caroline.perdrix@pierre-fabre.com; INVESTORS: John Elicker of
Bristol-Myers Squibb Company, +1-212-546-3775,
john.elicker@bms.com
|
